Straylight levels could be linked to corneal healing

Article

Straylight values improve over time and can be linked to the progression of corneal healing, according to a paper.

Straylight values improve over time and can be linked to the progression of corneal healing, according to a paper.

The prospective study, led by Dr Yan Wang, Tianjin Eye Hospital & Eye Institute, Ophthalmology and Visual Science Key Laboratory, Tianjin Medical University, Tianjin, China, involved 128 consecutive eyes from 66 patients. Thin-flap LASIK with a femtosecond laser was performed in 61 eyes of 31 patients and think-flap LASIK with mechanical microkeratome was performed in 67 eyes of 35 patients.

All eyes were ablated using the VIXS S4 excimer laser system after flap creation. Straylight values were measured with the C-Quant straylight meter preoperatively, 1 day, 1 week, 1 month, 6 months and 1 year postoperatively.

The mean preoperative straylight values were 0.93 ± 0.11 but the postoperative values were 1.00 ± 0.11, 0.98 ± 0.10, and 0.99 ± 0.12 at 1 day, 1 week, and 1 month, respectively in the femtosecond thin-flap LASIK group. These values decreased and returned to the preoperative levels and 6 months and 1 year postoperatively.

The postoperative-preoperative increases in straylight were more reduced in the femtosecond laser group compared to the mechanical microkeratome group at 0.05 ± 0.13 vs 0.10 ± 0.13 at 1 month postoperatively. There was a significant negative correlation between preoperative straylight values and postoperative-preoperative increases.

Straylight levels return to preoperative levels and the results indicate this could be related to the progression of corneal healing.

Please visit the Journal of Refractive Surgery to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.